<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stroes, Erik</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PCSK9 Inhibitor Slashes LDL-C in Statin-Intolerant Patients (GAUSS-2)</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">Approximately 10% to 20% of patients treated with statins experience side effects, primarily musculoskeletal side effects, which diminish compliance or cause discontinuation of therapy [Zhang H et al. Ann Intern Med 2013; Mancini GB et al Can J Cardiol 2011]. Evolocumab, a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced levels of low-density lipoprotein cholesterol (LDL-C) to a greater extent than ezetimibe in hypercholesterolemic patients who could not tolerate effective doses of statins. This article presents the results from a double-blind multicenter Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 2 study [GAUSS-2; Stroes E et al. J Am Coll Cardiol 2014].</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>